Tislelizumab
BGB-A317-303
Phase 3 small_molecule completed
Quick answer
Tislelizumab for Non-small Cell Lung Cancer is a Phase 3 program (small_molecule) at BeiGene with 2 ClinicalTrials.gov record(s).
Program details
- Company
- BeiGene
- Indication
- Non-small Cell Lung Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed